131852-53-4

Basic information

• Product Name: (S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE
• Synonyms: TERT-BUTYL(S)-1-BENZYLPYRROLIDIN-3-YLCARBAMATE;(S)-1-BENZYL-3-(TERT-BUTOXYCARBONYLAMINO)PYRROLIDINE;(S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE;(S)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE;(s)-n-benzyl-3-boc-amino Pyrrolidine;(S)-1-BENZYL-3-N-BOC-AMINO-PYRROLIDINE;(S)-Tert-butyl 1-benzylpyrrolidin-3-ylcarbamate;(S)-(1-Benzyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester
• CAS NO: 131852-53-4
• Molecular Formula: C₁₆H₂₄N₂O₂
• Molecular Weight: 276.37
• Mol File: 131852-53-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 77-81 °C(lit.)
• Boiling Point: 385.142 °C at 760 mmHg
• Flash Point: 186.727 °C
• Appearance: /
• Density: 1.089 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: 2-8°C
• PKA: 12.31±0.20(Predicted)
• CAS DataBase Reference: (S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE(131852-53-4)
• EPA Substance Registry System: (S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE(131852-53-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 131852-53-4(Hazardous Substances Data)

Usage

General Description

(S)-(-)-1-Benzyl-3-(BOC-amino)pyrrolidine is a chemical compound that includes components like benzyl and BOC-amino, included in its complex structure. (S)-(-)-1-BENZYL-3-(BOC-AMINO)PYRROLIDINE belongs to the family of Pyrrolidines, characterized by a pyrrolidine ring, a five-membered heterocyclic compound. The specific molecular structure of this chemical includes a benzyl group, which is basically a phenyl group attached to a methane group, and a BOC-amino, which is a type of amine protected by a BOC group, used for preventing unwanted secondary reactions during chemical syntheses. The compound is predominantly used in advanced organic synthesis and pharmaceutical manufacturing. Its stereo-specificity, indicated by the (S)-(-) label, suggests potential uses in creating chiral molecules for the pharmaceutical industry.

InChI:InChI=1/C16H24N2O2/c1-16(2,3)20-15(19)17-14-9-10-18(12-14)11-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,17,19)/t14-/m0/s1

Upstream product

• 100-52-7 benzaldehyde 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 128427-10-1 (S)-2-(tert-butoxycarbonylamino)-1,4-butanediol 
• 130622-08-1 dimethyl N-tert-butoxycarbonyl-L-aspartate 
• 114715-35-4 (R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine 
• 114636-29-2 (3S)-3-azido-1-(phenylmethyl)pyrrolidine 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114715-38-7 (3S)-1-benzyl-3-pyrrolidinamine 
• 100-46-9 benzylamine 
• 176970-13-1 [(S)-2-(tert-butoxycarbonyamino)butane-1 ,4-diyl dimethanesulfonate] 

Downstream Products

• 169749-99-9 (3S)-(-)-1-benzyl-3-(methylamino)pyrrolidine 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 114636-30-5 (S)-(-)-1-benzyl-3-acetylaminopyrrolidine 
• 178688-10-3 ((S)-1-Cyclohexyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester 
• 114715-38-7 (3S)-1-benzyl-3-pyrrolidinamine 

Relevant articles and documents

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands

A series of naphthamides were synthesized, and the affinities of these compounds were determined for dopamine D2 and D3 receptors using radioligand binding techniques. The naphthamide compounds that were prepared include N-(1- alkylp

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.